000 03396cam a2200457 4500500
005 20250121155500.0
041 _afre
042 _adc
100 1 0 _aDe, Dipankar
_eauthor
700 1 0 _a Shilpa, Shilpa
_eauthor
700 1 0 _a Kumar, Sheetanshu
_eauthor
700 1 0 _a Drenovska, Kossara
_eauthor
700 1 0 _a Mehta, Hitaishi
_eauthor
700 1 0 _a van Beek, Nina
_eauthor
700 1 0 _a Sachdeva, Naresh
_eauthor
700 1 0 _a Fleva, Alexandra
_eauthor
700 1 0 _a Shahid, Martin
_eauthor
700 1 0 _a Handa, Sanjeev
_eauthor
700 1 0 _a Giannakou, Anastasia
_eauthor
700 1 0 _a Naumova, Elissaveta
_eauthor
700 1 0 _a Mahajan, Rahul
_eauthor
700 1 0 _a Kyriakou, Aikaterini
_eauthor
700 1 0 _a Lesichkova, Spaska
_eauthor
700 1 0 _a Lazaridou, Elisabeth
_eauthor
700 1 0 _a Dass Radotra, Bishan
_eauthor
700 1 0 _a Kishore, Kamal
_eauthor
700 1 0 _a Schmidt, Enno
_eauthor
700 1 0 _a Vassileva, Snejina
_eauthor
700 1 0 _a Patsatsi, Aikaterini
_eauthor
245 0 0 _aDifferences among Indian and European pemphigus patients based on demographics, clinical parameters and propensity for relapse: results of a prospective bicontinental cohort study
260 _c2023.
500 _a53
520 _aBackgroundLimited studies have explored pemphigus variations among different ethnic groups residing in their respective geographical locations.ObjectivesThis bicontinental study aimed to compare clinical and immunological parameters in Indian and European pemphigus patients in complete remission, off therapy, or on minimal therapy.Materials & Methods105 patients (India, n= 75; Bulgaria, n=15; Greece, n=15) with pemphigus vulgaris (PV) or pemphigus foliaceous (PF) in complete remission on minimal therapy (n=64) or complete remission off therapy (n=41) were recruited. Demographic, clinical, and immunological parameters were compared.ResultsIndian patients were significantly younger, the maximal disease severity during the preceding active disease phase was significantly lower, and treatment duration until complete remission was significantly shorter, compared to European patients. European patients had significantly higher anti-Dsg3 serum levels and higher IgG positivity rate based on direct immunofluorescence microscopy at baseline. Furthermore, European patients revealed higher CD19, CD19+ CD27+ cell counts, compared with patients from India. Of note, none of the European patients (n=30) relapsed within the study period, in contrast to 29/75 (38.6%) Indian patients. Treatment strategies differed significantly between the two cohorts, with more frequent utilization of rituximab to achieve remission in the Indian cohort, while prednisolone was more widely used for maintaining remission in the European cohort.ConclusionThe observed heterogeneity of pemphigus among patients of different ethnicities in terms of demographics, clinical parameters, and propensity for relapse may be due to genetic background or different treatment strategies.
690 _adesmoglein 3
690 _arelapse
690 _aethnicity
690 _adisease severity
690 _apemphigus
786 0 _nEuropean Journal of Dermatology | 33 | 6 | 2023-11-01 | p. 642-647 | 1167-1122
856 4 1 _uhttps://shs.cairn.info/revue-european-journal-of-dermatology-2023-6-page-642?lang=en&redirect-ssocas=7080
999 _c604878
_d604878